Adult Double-Chambered Right Ventricle Associated With Ventricular Tachycardia and New-Onset Heart Failure

Patibandla, Saikrishna; Trehan, Siddhant; Kyaw, Htoo; Tsai, Kevin; Reddy, Sarath

doi:10.7759/cureus.8122

Cited by 6 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Spironolactone: Spironolactone, an aldosterone inhibitor originally used as an effective diuretic for the treatment of high blood pressure and edema, was subsequently shown to benefit patients with heart failure. [369][370][371] Increasingly, studies have shown the anticancer properties of spironolactone on prostate and breast cancer. 372,373 Regulation of DNA damage response appears to be the key mechanism of spironolactone in cancer treatment.…”

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

391

315

View full text Add to dashboard Cite

Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The "treasure trove" of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono-or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake.

show abstract

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

391

315

View full text Add to dashboard Cite

show abstract

“…Therefore, the relationship between spironolactone and the treatment of hair loss is related to the role of spironolactone in reducing androgens. 8,22 It was reported that spironolactone could reduce the symptoms of FPHL not only in adult women but also in a nine-year-old girl. 23 Meanwhile, studies have shown different results regarding the efficacy of finasteride.…”

Section: Discussionmentioning

confidence: 99%

“…With the reduction in androgen production, hair that has become thin and weak due to high secretion of these hormones becomes thick again and returns to its normal state. Therefore, the relationship between spironolactone and the treatment of hair loss is related to the role of spironolactone in reducing androgens 8,22 . It was reported that spironolactone could reduce the symptoms of FPHL not only in adult women but also in a nine‐year‐old girl 23 …”

Section: Discussionmentioning

confidence: 99%

The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial

Sadeghzadeh Bazargan,

Tavana,

Dehghani

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

IntroductionAndrogenic alopecia (AGA) is the most common cause of hair loss in women, affecting their quality of life. The present study was conducted with the aim of comparing the combined effect of topical minoxidil and oral spironolactone with the combined effect of topical minoxidil and oral finasteride in women with AGA, female and male hair loss patterns.MethodThis clinical study was performed on 60 women suffering from AGA. The patients were divided into two groups receiving spironolactone 100 mg/day and finasteride 5 mg/day. In addition, a 2% minoxidil solution was used in all patients in addition to treatment with finasteride or spironolactone. At 2 months after initiation and at the end of treatment, patients were evaluated using the Ludwig/Norwood–Hamilton scale and the degree of physician and patient satisfaction.ResultsAfter 2 months, hair density, hair thickness, and hair loss had improved in both groups; however, statistically, there was no significant difference between the two groups with respect to these parameters (p > 0.05). After 4 months, a significant difference was found between the two groups in terms of treatment response (physician satisfaction), hair density, and hair loss severity. So that, the drugs used were ineffective in 6.7% of cases in the minoxidil‐spironolactone group and in 16.7% of cases in the minoxidil‐finasteride group. In addition, 43.3% of cases in the minoxidil‐spironolactone group and 53% in the minoxidil‐finasteride group responded well to treatment. The treatment effect was excellent in 56.7% and 0% of the mentioned groups, respectively, and the mentioned difference was statistically significant (p: 0.01). The response to treatment in female pattern hair loss (FPHL) was not statistically significant (p: 0.52), but there was a significant difference in the response to both treatments in male pattern hair loss (MPHL; p: 0.007). In terms of patient satisfaction, minoxidil‐spironolactone treatment was significantly better than minoxidil‐finasteride regarding hair density and severity of hair loss (p: 0.01). Finally, in terms of treatment complications, the patients in two groups did not have any serious adverse effects.ConclusionThe combination of minoxidil and spironolactone could be considered a more effective treatment than the combination of minoxidil and finasteride in women with AGA, FPHL, and MPHL.

show abstract

“…This side effect is higher risk in individuals >45 years of age or with underlying renal disease (Hayes et al, 2022). It may also be associated with polyuria, orthostasis, and drowsiness (Patibandla et al, 2023). Lastly, there is some concern for premature breast bud fusion with spironolactone, although this concern requires further investigation (Wierckx et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study

Burgener,

DeBosch,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundBicalutamide is a potential anti-androgen for transgender individuals with feminizing embodiment goals, but use has been limited because of hepatotoxicity in cisgender men with prostate cancer. This study compared transaminase changes in transfeminine adolescents and young adults (AYA) using low-dose bicalutamide with individuals using other methods of androgen blockade.MethodsA retrospective analysis was conducted using electronic health record data for patients starting gender affirming hormone therapy with at least 10 months of follow-up data between 2015 and 2023. Linear mixed models compared change in ALT and AST from baseline and maximum ALT and AST values in bicalutamide and comparison groups. Secondary outcomes included % individuals with ALT and AST elevation more than 1, 2, or 3 times the upper limit of normal (ULN) (Fisher’s exact test), standardized mean estradiol dose by group (t test), and Tanner staging of breast tissue by group (Fisher’s exact test).ResultsEighty-four transfeminine AYA (median age 18) taking bicalutamide were compared to 69 transfeminine AYA (median age 19) taking GnRH agonists, spironolactone or no agent in addition to estradiol. In linear mixed models adjusted for baseline age, BMI, baseline ALT or AST, and alcohol use, there was no difference in delta or maximum ALT or AST in bicalutamide and comparison groups. No individuals had an AST or ALT level > 3x ULN. Estradiol doses and Tanner stages were similar between groups in a subgroup analysis of individuals receiving pediatric care.ConclusionBicalutamide was not associated with significant change in transaminases as compared with other anti-androgen regimens over one year. Bicalutamide appears to be a safe anti-androgen for transfeminine individuals at low dose with close monitoring and deserves further study.

show abstract

Adult Double-Chambered Right Ventricle Associated With Ventricular Tachycardia and New-Onset Heart Failure

Cited by 6 publications

References 11 publications

Overcoming cancer therapeutic bottleneck by drug repurposing

Overcoming cancer therapeutic bottleneck by drug repurposing

The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial

Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study

Contact Info

Product

Resources

About